OOIR: Observatory of International Research

Papers

(The TQCC of Drugs is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences	490
Teclistamab: First Approval	465
Senaparib: First Approval	276
Targeting DNA Damage Response Deficiency in Thoracic Cancers	247
Spesolimab for the Treatment of Generalized Pustular Psoriasis	242
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression	219
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments	191
Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”	165
Eftrenonacog Alfa: A Review in Haemophilia B	161
Acknowledgement to Referees	155
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema	146
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using	143
Epcoritamab: First Approval	140
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled,	138
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments	138
Vorasidenib: First Approval	124
New Therapies on the Horizon for Primary Biliary Cholangitis	123
Authors’ Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations	122
Aprocitentan: First Approval	109
Aztreonam-Avibactam: A Review in the Treatment of Serious Bacterial Infections Caused by Aerobic Gram-Negative Organisms	103
Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial	102
Repotrectinib: First Approval	100
Ivarmacitinib Sulfate: First Approval	99
Acoltremon: First Approval	98
Cosibelimab: First Approval	92

Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine	91
Olipudase Alfa: First Approval	89
QT Prolongation and Risk of Death with the Use of Methadone for Chronic Cancer and Noncancer Pain: Myths or Reality?	88
Danicopan: First Approval	87
Tolebrutinib: First Approval	86
Advances in Pharmacotherapy for Menopausal Vasomotor Symptoms	84
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer	83
Drugs in Development to Manage Acute Pain	81
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure	80
Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies	79
Efficacy and Harms of Opioid Analgesics for Acute Pain: Overview of Systematic Reviews and Meta-analyses	77
Lenacapavir: First Approval	77
Androgenetic Alopecia: Therapy Update	75
Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?	75
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection	72
Cancer Pain Treatment Strategies in Patients with Cancer	68
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids	67
Sibeprenlimab: First Approval	65
Delgocitinib 20 mg/g Cream: A Review in Chronic Hand Eczema	65
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification	64
Mosunetuzumab: First Approval	64
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?	64
Taletrectinib: First Approval	63
Situational Prevention of Migraine Attacks: Can Early Treatment Change the Conversation?	63
Mazdutide: First Approval	63
Tovorafenib: First Approval	62
Pozelimab: First Approval	60
Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes	58
Correction to: Tapinarof Cream 1%: First Approval	58
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned	57
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer	57
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough	56
Targeting Inflammation in Bronchiectasis	56
Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology	56
Managing Burning Mouth Syndrome: Current and Future Directions	54
Dorzagliatin: First Approval	53
Sunvozertinib: First Approval	53
Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis	53
Correction to: Prevention and Treatment of Monkeypox	53
Ifupinostat: First Approval	53
Pixavir Marboxil: First Approval	51
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options	48
Pan-JAK Inhibition Across Chronic Hand Eczema and Other Cutaneous Diseases: An Updated Review on Topical Delgocitinib	47
Correction to: Concizumab: First Approval	47
The Place of Cannabinoids in the Treatment of Gynecological Pain	47
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab	46
Focus on Metformin: Its Role and Safety in Pregnancy and Beyond	46
Birch Bark Extract: A Review in Epidermolysis Bullosa	44
Correction: From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology	44
Ozoralizumab: First Approval	43

Gepirone Extended-Release: First Approval	42
Pharmacological Management of Obesity in Pregnancy: A Review of Current and Emerging Therapies	42
Targeting HER2 in Metastatic Colorectal Cancer: Current Therapies, Biomarker Refinement, and Emerging Strategies	42
Correction to: Remdesivir: A Review in COVID-19	41
Catumaxomab: First Approval	41
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’	41
Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses	40
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials	40
Antiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades	40
Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?	40
Tirzepatide: A Review in Type 2 Diabetes	39
Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study	39
Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults	39
Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy	39
Current and Emerging Treatments for Acid Sphingomyelinase Deficiency	39
Givinostat: First Approval	39
Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review	39
Update on Mpox Management: Epidemiology, Vaccines and Therapeutics, and Regulatory Changes	39
Correction: Teprotumumab: A Review in Thyroid Eye Disease	38
Sequential Use of Trastuzumab Deruxtecan and Sacituzumab Govitecan in Patients with Breast Cancer: A Pharmacological Approach to Support the Clinical Rationale	38
Correction: Ifupinostat: First Approval	38
Ensitrelvir Fumaric Acid: First Approval	38
Atrasentan: First Approval	38
Fezolinetant: First Approval	37
Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study	37
Polidocanol in Sclerotherapy for Lymphovenous Disorders: Mechanisms, Clinical Uses, and Future Prospects	36
Becotatug Vedotin: First Approval	36
Futibatinib: First Approval	35
Current Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy	35
Antifungal Treatment Regimens as Primary Therapy for Invasive Aspergillosis: A Systematic Review and Network Meta-analysis	35
Eye Involvement and Management in Inherited Epidermolysis Bullosa	35
Avacincaptad Pegol: First Approval	35
Oral Gut-Restricted Targeted Therapy for IBD: A Pipeline Review	34
Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets	34
Correction: Iptacopan: First Approval	34
Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations	34
Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 1	34
Beremagene Geperpavec: First Approval	33
Managing Pain in Fibromyalgia: Current and Future Options	33
Zeprumetostat: First Approval	33
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?	33
Effectiveness of Interventions to Reduce Opioid Use After Orthopaedic Surgery: A Systematic Review of Randomised Controlled Trials	33
Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries	33
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases	32
Lotilaner Ophthalmic Solution 0.25%: First Approval	32
Imetelstat: First Approval	32
Zastaprazan: First Approval	32
Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease	32
Acknowledgement to Referees	31
Varenicline Solution Nasal Spray: A Review in Dry Eye Disease	31
Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry	31
Mavorixafor: First Approval	30
Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management	30
Crinecerfont: First Approval	29
Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews	29
Diagnosis and Treatment of AL Amyloidosis	29
Retifanlimab: First Approval	29
Nogapendekin alfa Inbakicept: First Approval	29
Sepiapterin: First Approval	29
Revumenib: First Approval	29
Direct-Acting Antivirals and the Risk of Arrhythmias and Conduction Disorders in Patients with Chronic Hepatitis C: A French Nationwide Cohort Study	28
Immune Mechanisms in Epileptogenesis: Update on Diagnosis and Treatment of Autoimmune Epilepsy Syndromes	28
Revolutionary Changes in the Management of Lupus Nephritis: Towards De-Glucocorticoid or No-Glucocorticoid	28
Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval	28
Efficiency and Safety of Noninvasive and Intravesical Therapy for Adult Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials	28
Correction to: Spesolimab: First Approval	27
Comment on: “Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study”	27
Tradipitant: First Approval	27
Antibacterials with Novel Chemical Scaffolds in Clinical Development	27
Correction to: Sparsentan: First Approval	27
Zolbetuximab: First Approval	27
Methadone for Cancer Pain Management in Children: A Review of Literature	27
Onradivir: First Approval	27
Correction: Zastaprazan: First Approval	27
Remdesivir: A Review in COVID-19	27